DOCSLIB.ORG

Instituto Finlay

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Instituto Finlay Resumen de la información publicada por la OMS sobre los candidatos vacunales contra la COVID-19 en desarrollo a nivel mundial Última actualización por la OMS: 9 de abril de 2021. Fuente de información utilizada: 87 candidatos vacunales en evaluación clínica y 186 en evaluación preclínica. Candidatos vacunales en evaluación clínica por plataforma Candidatos vacunales más avanzados a nivel global Desarrollador de la vacuna/fabricante/país Plataforma de la vacuna Fase Sinovac/China Virus Inactivado 4 Wuhan Institute of Biological Products/Sinopharm/China Virus Inactivado 3 Beijing Institute of Biological Products/Sinopharm/China Virus Inactivado 3 University of Oxford/AstraZeneca/Reino Unido Vector viral no replicativo 4 CanSino Biological Inc./Beijing Institute Biotechnology/China Vector viral no replicativo 3 Gamaleya Research Institute/Rusia Vector viral no replicativo 3 Janssen Pharmaceutical Companies/Estados Unidos Vector viral no replicativo 3 Novavax/Estados Unidos Subunidad proteica 3 Moderna/NIAID/Estados Unidos ARN 4 BioNTech/Fosun Pharma/Pfizer/Estados Unidos ARN 4 Anhui Zhifei Longcom Biopharmac./Inst. Microbiology, Chinese Academy Sciences Subunidad proteica 3 CureVac AG/Alemania ARN 3 Institute of Medical Biology/Chinese Academy of Medical Sciences Virus inactivado 3 Research Institute for Biological Safety Problems, Kazakhstan Virus inactivado 3 Zydus Cadila Healthcare Ltd./India ADN 3 Bharat Biotech/India Virus Inactivado 3 Sanofi Pasteur + GSK/Francia/Gran Bretaña Subunidad proteica 3 Instituto Finlay de Vacunas/Cuba Subunidad proteica 3 Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"/Rusia Subunidad proteica 3 Center for Genetic Engineering and Biotechnology (CIGB) Subunidad proteica 3 Candidatos vacunales mucosales en evaluación clínica Vía de adminsitra- Desarrollador de la vacuna/fabricante/país Plataforma de la vacuna ción Fase Symvivo/Canadá ADN Oral 1 Codagenix/Serum Institute of India Virus vivo atenuado Intranasal 1 Vaxart/Estados Unidos Vector viral no replicativo Oral 1 University of Oxford No Dato Intranasal 1 ImmunityBio, Inc./Estados Unidos Vector viral no replicativo Oral 1 Center for Genetic Engineering and Biotechnology (CIGB)/Cuba Subunidad proteica Intranasal 1/2 Altimmune, Inc./Estados Unidos Vector viral no replicativo Intranasal 1 University of Hong Kong, Xiamen University and Beiging Wantai Biological Pharmacy No Dato Intranasal 2 Bharat Biotech International Limited/India Vector viral no replicativo Intranasal 1 Razi Vaccine and Serum Research Institute Subunidad proteica Intranasal 1 Meissa Vaccines, Inc. Virus vivo atenuado Intranasal 1 Noticias en la Web Cuba y China colaboran para crear "una vacuna de amplio espectro contra muchos coronavirus" 1 apr. La fortaleza de Cuba en para el desarrollo, tanto de los sectores de la biotecnología moléculas terapéuticas como de y la industria farmacéutica ha candidatos vacunales, bajo el facilitado que tenga capacidad cumplimiento de todas las de crear al mismo tiempo hasta regulaciones establecidas por las cinco posibles vacunas contra el respectivas agencias", debido a covid-19, afirma la directora que en situaciones así "uno general del Centro de Ingeniería acomoda los cronogramas y Genética y Biotecnología (CIGB) estrategias para dar respuesta cubano, Marta Ayala Ávila. rápida a la situación", explicó Entre los fármacos anticovid que esta especialista. desarrolla esa nación Proyecto Pan-Corona latinoamericana destacan La directora del CIGB aclara que Soberana, Mambisa y Abdala, los científicos cubanos solo cuyos ensayos clínicos avanzan emplearon tecnología y recursos con rapidez y algunos ya se humanos nacionales para crear encuentran en la fase III de los sus medicamentos, así como "cuando tiene algo que mostrarle al experimentos. anticuerpos producidos en la isla, mundo": "los enemigos intentan "En esta época de la pandemia y que esos fármacos son minimizar cualquier logro que se han acortado los tiempos "susceptibles a ser combinados" tengamos; de hecho, el bloqueo con otras vacunas. también afecta a las investigaciones Asimismo, Cuba trabaja con científicas, a la biotecnología y al China para poner en marcha el sector farmacéutico" cubanos. proyecto Pan-Corona y lograr No obstante, esta limitación otra vacuna contra una nueva impuesta por EE.UU. supone un cepa del virus SARS-CoV-2, desafío para la comunidad científica causante del covid-19, una de Cuba que, pese a los obstáculos iniciativa cuyo objetivo es lograr y gracias a la inversión realizada por un fármaco de amplio espectro el Gobierno cubano en educación y contra "muchos coronavirus". recursos humanos, está en Respecto a las críticas hacia los condiciones de desarrollar candidatos vacunales cubanos, tecnología propia. Marta Ayala Ávila asevera que no es la primera vez que se intenta El país caribeño tiene "la desacreditar a La Habana capacidad productiva y los recursos humanos para desarrollar cinco candida- tos vacunales", afirma Fuente: RUSSIA TODAY. Disponible en https://cutt.ly/tcTo4TJ Marta Ayala Ávila, direc- tora general del Centro de Ingeniería Genética y Bio- tecnología cubano.” Cuba Produces Medical Equipment To Treat COVID 2 apr. State-owned companies Yero, founder of Cuba's being tested in its Phase III in the in Havana have unveiled Cuban- Immunoassay Center and Advisor eastern city of Santiago de Cuba made medical equipment used to Biocubafarma, on Wednesday. with 40,000 patients and with in treating COVID-19. There are currently 23,168 another 120,000 volunteers in an The companies are producing patients of COVID-19 in Cuba's "intervention study." high-end respirators, reagents hospitals. Mambisa, Soberana 01, and and plastic supplies that The first dose of the Phase III Soberana Plus (02), are the other alongside Cuba's COVID-19 study of the Soberana 02 antigens in development but that are vaccines are allowing the island vaccine, have been administered. in still earlier stages. nation to address health care The Soberana 02 study was Authorities expect Phase III of issues created by the worldwide tested by injecting 44,000 people Soberana 02 and Abdala to be pandemic. who were joined by 150,000 completed in June, which will pave "The development of medical Cubans in the capital who were the way for mass immunization on equipment and technologies included in "intervention studies" the island of 11-million people. allows us to achieve sovereignty to obtain more data on the Cuba has registered some 75,263 in many aspects... and also in behavior of the antigen. cases of COVID-19 and 424 deaths the diagnosis of COVID-19," The other advanced vaccine from the virus since the beginning of stated José Luis Fernández under study is Abdala, which is the pandemic in March 2020. Fuente: REPUBLICWORLD.COM. Disponible en https://cutt.ly/jcTwnXD Alérgicos al tiomersal podrán vacunarse con candidatos de Cuba 3 abr. Las personas alérgicas al Nacional de Biopreparados de la 'Ello sirve como preservo para tiomersal podrán vacunarse con nación caribeña, los últimos lotes garantizar la conservación de la candidatos antiCovid-19 de con una sola dosis hechos hasta esterilidad del bulbo que, Cuba, para lo cual ya se ahora y otros a originar en el necesariamente, será intervenido producen lotes monodosis sin futuro, no contendrán tiomersal. varias veces para administrar cada ese compuesto organomercúrico 'En el estudio de intervención con una de las dosis', expuso la con acción antiséptica, anunció Soberana 02 que se aplica a los especialista. hoy aquí una autoridad científica. trabajadores de la salud de La Puntualizó, además, que los En declaraciones al diario digital Habana, ya se han usado lotes primeros lotes monodosis lo Cubadebate, la directora de sin dicho conservante con contenían, justamente porque Investigaciones del Instituto mercurio', detalló. pertenecen a una etapa de Finlay de Vacunas (IFV), Dagmar La experta señaló que, en el caso desarrollo y producciones a baja García, dijo que habrá vacunas de ese candidato, a cargo del IFV escala. para todos esos sujetos excluidos y actualmente también en fase III De acuerdo con la experta, es de los actuales ensayos clínicos de ensayos clínicos en la capital frecuente en la industria por dicha causa. cubana, las presentaciones farmacéutica la presentación de las Precisó que, como parte del multidosis siempre contienen vacunas en formulaciones de varias escalado productivo en el Centro tiomersal. dosis, que pueden contener cinco o 10 por cada bulbo, lo cual facili- Por otro lado, la propuesta vacu- Dicho producto, cuyo nombre alude ta los grandes programas de in- nal Mambisa, del Centro de Inge- a un poema del Héroe Nacional de munización contra enfermeda- niería Genética y Biotecnología Cuba, José Martí, pasa por la fase III des infecciosas. de Cuba (CIGB), por ser un spray con una muestra de 48 mil personas Soberana 02 concluyó reciente- nasal, no contiene tiomersal. de tres provincias al Oriente del mente la primera etapa de su fa- Con relación al candidato Abdala, país; y será aplicado en más 120 mil se III con la inyección de la do- la directora general del CIGB, incluidos en estudios intervenciona- sis inicial a 44 mil 10 voluntarios Marta Ayala, confirmó que se tra- les en La Habana y territorios del previstos en el estudio y llegará baja a nivel de escala productiva centro de esta nación. a otros 150 mil durante el ensa- en vacunas sin tiomersal para yo de intervención controlado. etapas clínicas futuras. Fuente: PRENSA LATINA. Disponible en https://cutt.ly/BcTrEzh
Load more

Recommended publications
  • Puzzling Inefficiency of H5N1 Influenza
    Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry Jeong-Ki Kima,b, Ghazi Kayalia, David Walkera, Heather L. Forresta, Ali H. Ellebedya, Yolanda S. Griffina, Adam Rubruma, Mahmoud M. Bahgatc, M. A. Kutkatd, M. A. A. Alie, Jerry R. Aldridgea, Nicholas J. Negoveticha, Scott Kraussa, Richard J. Webbya,f, and Robert G. Webstera,f,1 aDivision of Virology, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105; bKorea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Republic of Korea; cDepartment of Infection Genetics, the Helmholtz Center for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany; dVeterinary Research Division, and eCenter of Excellence for Advanced Sciences, National Research Center, 12311 Dokki, Giza, Egypt; and fDepartment of Pathology, University of Tennessee Health Science Center, Memphis, TN 38106 Contributed by Robert G. Webster, May 10, 2010 (sent for review March 1, 2010) In Egypt, efforts to control highly pathogenic H5N1 avian influenza virus emulsion H5N1 vaccines imported from China and Europe) virus in poultry and in humans have failed despite increased have failed to provide the expected level of protection against the biosecurity, quarantine, and vaccination at poultry farms. The ongo- currently circulating clade 2.2.1 H5N1 viruses (21). Despite the ing circulation of HP H5N1 avian influenza in Egypt has caused >100 attempted implementation of these measures, the current strat- human infections and remains an unresolved threat to veterinary and egies have limitations (22). public health. Here, we describe that the failure of commercially avail- Antibodies to the circulating virus strain had been detected in able H5 poultry vaccines in Egypt may be caused in part by the passive day-old chicks in Egypt (see below).
    [Show full text]
  • RNA Viruses As Tools in Gene Therapy and Vaccine Development
    G C A T T A C G G C A T genes Review RNA Viruses as Tools in Gene Therapy and Vaccine Development Kenneth Lundstrom PanTherapeutics, Rte de Lavaux 49, CH1095 Lutry, Switzerland; [email protected]; Tel.: +41-79-776-6351 Received: 31 January 2019; Accepted: 21 February 2019; Published: 1 March 2019 Abstract: RNA viruses have been subjected to substantial engineering efforts to support gene therapy applications and vaccine development. Typically, retroviruses, lentiviruses, alphaviruses, flaviviruses rhabdoviruses, measles viruses, Newcastle disease viruses, and picornaviruses have been employed as expression vectors for treatment of various diseases including different types of cancers, hemophilia, and infectious diseases. Moreover, vaccination with viral vectors has evaluated immunogenicity against infectious agents and protection against challenges with pathogenic organisms. Several preclinical studies in animal models have confirmed both immune responses and protection against lethal challenges. Similarly, administration of RNA viral vectors in animals implanted with tumor xenografts resulted in tumor regression and prolonged survival, and in some cases complete tumor clearance. Based on preclinical results, clinical trials have been conducted to establish the safety of RNA virus delivery. Moreover, stem cell-based lentiviral therapy provided life-long production of factor VIII potentially generating a cure for hemophilia A. Several clinical trials on cancer patients have generated anti-tumor activity, prolonged survival, and
    [Show full text]
  • Study Toward the Development of Advanced
    STUDY TOWARD THE DEVELOPMENT OF ADVANCED INFLUENZA VACCINES DISSERTATION Presented in partial fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By Leyi Wang B.S.,M.S. Graduate Program in Veterinary Preventive Medicine The Ohio State University 2009 Dissertation Committee: Professor Chang-Won Lee, advisor Professor Y.M. Saif, Professor Daral J. Jackwood Professor Jeffrey T. LeJeune Copyright by Leyi Wang 2009 ABSTRACT Avian influenza is one of the most economically important diseases in poultry. Since it was found in Italy in 1878, avian influenza virus has caused numerous outbreaks around the world, resulting in considerable economic losses in poultry industry. In addition to affecting poultry, different subtypes of avian influenza viruses can infect many other species, thus complicating prevention and control. Killed and fowlpox virus vectored HA vaccines have been used in the field as one of effective strategies in a comprehensive control program to prevent and control avian influenza. Live attenuated vaccines for poultry are still under development. Live attenuated vaccines can closely mimic natural infection inducing long-lasting humoral and cellular immunity. In addition, they may be used for mass vaccination. However, concerns with spread of live vaccine viruses, mutation into virulent strains from live attenuated viruses, and reassortment of vaccine and field strains prevent recommending live vaccines as poultry vaccines in the field. For this reason, there are increasing interests in the development of in ovo vaccines that can reduce the risk of spreading the vaccine virus. Therefore, in the first three parts of our study, we have explored several strategies (NS1 truncation, temperature sensitive (ts) mutations, HA substitution, and non-coding region (NCR) mutations) to attenuate viruses to reach this goal.
    [Show full text]
  • Vaccines: Past, Present and Future
    HISTORICAL PERSPECTIVE Vaccines: past, present and future Stanley A Plotkin The vaccines developed over the first two hundred years since Jenner’s lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur’s early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines. http://www.nature.com/naturemedicine “The Circassians [a Middle Eastern people] perceived that of a thou- mild illness in humans, could prevent smallpox. This discovery not sand persons hardly one was attacked twice by full blown smallpox; only led to the eradication of smallpox in the twentieth century, but that in truth one sees three or four mild cases but never two that are also gave cachet to the idea of deliberate protection against exposure serious and dangerous; that in a word one never truly has that illness to infectious diseases. twice in life.” The history of vaccination as a deliberate endeavor began in the Voltaire, “On Variolation,” Philosophical Letters, 1734 laboratory of Louis Pasteur.
    [Show full text]
  • The Immunological Basis for Immunization Series
    The Immunological Basis for Immunization Series Module 23: Influenza Vaccines Immunization, Vaccines and Biologicals The immunological basis for immunization series: module 23: influenza vaccines (Immunological basis for immunization series; module 23) ISBN 978-92-4-151305-0 © World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The immunological basis for immunization series: module 23: influenza vaccines. Geneva: World Health Organization; 2017 (Immunological basis for immunization series; module 23). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Reported on January 27, 2020
    Introduction 3 Executive Summary 5 Chapter 1 Second Round of Survey : Data Analysis 10 Chapter 2 Comparative Analysis (2020 and 2021) 37 Chapter 3 A Discourse on Pandemic Viruses and Vaccines -PVS Kumar 60 Chapter 4 Persisting Socio-economic Crisis: COVID-19 Lays Bare the Social Fault Lines1 - Prof. Arun Kumar 96 Annexure 1 113 Annexure 2 120 Annexure 2a 129 Index 1 The Second Pulse of the Pandemic : A Sudden Surge in Scientic Temper during the Covid-19 Crisis © Anhad 2021 Acknowledgement : PM Bhargava Foundation We are thankful to the following for helping us collect the data : Bhavesh Bariya Bhavna Sharma Deshdeep Dhankar Dev Desai Farida Khan Farhat Khan Jagori Rural Manish Kumar Ray Manisha Trivedi Mukhtar Shaikh Nazneen Shaikh Published by : Printed by : Pullshoppe 9810213737 2 Introduction Scientific community rises to the occasion Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), after mutation, found a new host, the human cell, and comfortably multiplied itself. Used human cells as copying machines and made millions of copies in nasal cavities, throats and lungs at times in human eyes, which could survive in aerosols and various surfaces for more than 72 hours. The human bodies proved to be secured habitable housing colonies, which not only offered environment for its multiplication within the body at an exponential rate but also helped it to travel all over the globe. Within human cells it also mutated, changed in shape and content, and became extra virulent, which made it extremely difficult to suppress or impede its propagation. Evidently, the virus showed no signs of leaving the newfound housing complexes in a hurry.
    [Show full text]
  • Evaluation of in Ovo Vaccination of DNA Vaccines for Campylobacter Control in Broiler Chickens ⇑ Xiang Liu, Lindsay Jones Adams, Ximin Zeng, Jun Lin
    Vaccine 37 (2019) 3785–3792 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Evaluation of in ovo vaccination of DNA vaccines for Campylobacter control in broiler chickens ⇑ Xiang Liu, Lindsay Jones Adams, Ximin Zeng, Jun Lin Department of Animal Science, The University of Tennessee, 2506 River Drive, Knoxville, TN 37996, USA article info abstract Article history: Campylobacter is the leading bacterial cause of human enteritis in developed countries. Chicken is a major Received 7 August 2018 natural host of Campylobacter. Thus, on-farm control of Campylobacter load in poultry would reduce the Received in revised form 13 May 2019 risk of human exposure to this pathogen. Vaccination is an attractive intervention measure to mitigate Accepted 20 May 2019 Campylobacter in poultry. Our previous studies have demonstrated that Campylobacter outer membrane Available online 3 June 2019 proteins CmeC (a component of multidrug efflux pump) and CfrA (ferric enterobactin receptor) are fea- sible and promising candidates for vaccine development. In this study, by targeting these two attractive Keywords: vaccine candidates, we explored and evaluated a new vaccination strategy, which combines the in ovo Campylobacter jejuni vaccination route and novel DNA vaccine formulation, for Campylobacter control in broilers. We observed DNA vaccine In ovo vaccination that direct cloning of cfrA or cmeC gene into the eukaryotic expression vector pCAGGS did not lead to suf- Poultry ficient level of production of the target proteins in the eukaryotic HEK-293 cell line. However, introduc- Kozak sequence tion of the Kozak consensus sequence (ACCATGG) in the cloned bacterial genes greatly enhanced production of inserted gene in eukaryotic cells, creating desired DNA vaccines.
    [Show full text]
  • Frequently Asked Questions on Viral Tumor Diseases Compiled by the AAAP Tumor Virus Committee (2012)
    Frequently Asked Questions on Viral Tumor Diseases Compiled by the AAAP Tumor Virus Committee (2012) 1. Can you expect 100% protection against MDV field challenge in vaccinated birds? No. As with all other vaccines, achieving 100% protection under field conditions is not possible from a biological viewpoint. In chicken flocks with healthy immune system and that are properly vaccinated and raised under adequate management, the losses are low without a significant impact on livability and/or performance. In cases of severe field challenge at an early age in vaccinated layers and breeders, mortality around 2-5% and broiler condemnations due to MD at ~0.05 % have been observed. 2. Which vaccine or vaccine combination may offer the best protection against field challenge in broilers, broiler breeders, or commercial layers? Broilers are vaccinated with HVT or HVT+SB1. HVT+SB1 is used in locations where very virulent (vv)MDVs are prevalent and the HVT vaccine alone does not provide an optimal protection. In some cases, particularly in heavy birds (e.g. roosters), HVT+SB1 may not provide adequate protection due to the prevalence of vv+MDV. In these circumstances, the bivalent HVT+CVI988(Rispens) or the trivalent HVT+SB1+CVI988(Rispens) vaccine has been used. Using below recommended dose of plaque forming units (PFU) is a common practice in broiler vaccination, however, it should be noted that this practice can lead to MD breaks in the face of severe field challenge and may play a role in accelerating MD virus evolution towards greater virulence. Breeders and Layers are commonly vaccinated with the HVT+CVI988(Rispens) vaccine using the full dose providing these long-lived birds with the broadest protection against MD.
    [Show full text]
  • Intranasal Powder Live Attenuated Influenza Vaccine Is
    www.nature.com/npjvaccines ARTICLE OPEN Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets Jasmina M. Luczo 1,2, Tatiana Bousse3, Scott K. Johnson1, Cheryl A. Jones1, Nicholas Pearce3, Carlie A. Neiswanger1, Min-Xuan Wang4, ✉ Erin A. Miller4, Nikolai Petrovsky 5,6, David E. Wentworth 3, Victor Bronshtein4, Mark Papania7 and Stephen M. Tompkins 1,2,8 Influenza viruses cause annual seasonal epidemics and sporadic pandemics; vaccination is the most effective countermeasure. Intranasal live attenuated influenza vaccines (LAIVs) are needle-free, mimic the natural route of infection, and elicit robust immunity. However, some LAIVs require reconstitution and cold-chain requirements restrict storage and distribution of all influenza vaccines. We generated a dry-powder, thermostable LAIV (T-LAIV) using Preservation by Vaporization technology and assessed the stability, immunogenicity, and efficacy of T-LAIV alone or combined with delta inulin adjuvant (Advax™) in ferrets. Stability assays demonstrated minimal loss of T-LAIV titer when stored at 25 °C for 1 year. Vaccination of ferrets with T-LAIV alone or with delta inulin adjuvant elicited mucosal antibody and robust serum HI responses in ferrets, and was protective against homologous challenge. These results suggest that the Preservation by Vaporization-generated dry-powder vaccines could be distributed without refrigeration and administered without reconstitution or injection. Given these significant advantages for vaccine distribution and delivery, further research is warranted. 1234567890():,; npj Vaccines (2021) 6:59 ; https://doi.org/10.1038/s41541-021-00320-9 INTRODUCTION cellular immune responses12. Although some LAIVs require Influenza viruses pose a dual threat to global human health— healthcare workers (HCWs) to mix the dry vaccine with a diluent, annual seasonal epidemics and sporadic global pandemics.
    [Show full text]
  • Study on In-Ovo Vaccination by Needle-Free Injection
    Proceedings of the 6th World Congress on New Technologies (NewTech'20) Prague, Czech Republic Virtual Conference – August, 2020 Paper No. ICBB 115 DOI: 10.11159/icbb20.115 Study on In-Ovo Vaccination by Needle-Free Injection Ko-Jung Huang1, Wei-Chih Chen1, Ching-Wei Cheng2 1 Department of Bio-industrial Mechatronics Engineering, National Chung Hsing University No.145 Xingda Rd., South Dist., Taichung City 402, Taiwan (R.O.C.) First. [email protected] 2 College of Intelligence, National Taichung University of Science and Technology No.129, Sec.3, Sanmin Rd, North Dist., Taichung City 404, Taiwan (R.O.C.) Third. [email protected] Extended Abstract Chick immunization in Taiwan in the current stage is done in the traditional artificial way via chick subcutaneous injection, eye drops, spray vaccine, or getting the vaccine mixed with feed and other methods for epidemic prevention. In addition to the traditional artificial way, in 1982, Sharma and Burmester proved the success of egg injection via Marek's vaccine immunization under normal laboratory conditions for the first time [1]. Eighty-five percent of the US chicken industry deployed egg injection as an important method of chicken embryo immunization. Presently, many countries have developed the automated egg syringe system. Due to congenital biological differences of individual eggs, the vaccine cannot be accurately injected; there is lack of control of the needle-hit position. This may affect the growth of the chicken embryo. Wakenell et al. Published the Marek's vaccine in 2002 and the efficacy of the vaccine. Sparring time at embryonic age of 18 days, vaccines in the amniotic cavity can be absorbed with other nutrients together with chicken embryo.
    [Show full text]
  • Puzzling Inefficiency of H5N1 Influenza Vaccines In
    Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry Jeong-Ki Kima,b, Ghazi Kayalia, David Walkera, Heather L. Forresta, Ali H. Ellebedya, Yolanda S. Griffina, Adam Rubruma, Mahmoud M. Bahgatc, M. A. Kutkatd, M. A. A. Alie, Jerry R. Aldridgea, Nicholas J. Negoveticha, Scott Kraussa, Richard J. Webbya,f, and Robert G. Webstera,f,1 aDivision of Virology, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105; bKorea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Republic of Korea; cDepartment of Infection Genetics, the Helmholtz Center for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany; dVeterinary Research Division, and eCenter of Excellence for Advanced Sciences, National Research Center, 12311 Dokki, Giza, Egypt; and fDepartment of Pathology, University of Tennessee Health Science Center, Memphis, TN 38106 Contributed by Robert G. Webster, May 10, 2010 (sent for review March 1, 2010) In Egypt, efforts to control highly pathogenic H5N1 avian influenza virus emulsion H5N1 vaccines imported from China and Europe) virus in poultry and in humans have failed despite increased have failed to provide the expected level of protection against the biosecurity, quarantine, and vaccination at poultry farms. The ongo- currently circulating clade 2.2.1 H5N1 viruses (21). Despite the ing circulation of HP H5N1 avian influenza in Egypt has caused >100 attempted implementation of these measures, the current strat- human infections and remains an unresolved threat to veterinary and egies have limitations (22). public health. Here, we describe that the failure of commercially avail- Antibodies to the circulating virus strain had been detected in able H5 poultry vaccines in Egypt may be caused in part by the passive day-old chicks in Egypt (see below).
    [Show full text]
  • In Ovo Immunization of Chickens for Newcastle Disease Using
    IN OVO IMMUNIZATION OF CHICKENS FOR NEWCASTLE DISEASE USING RECOMBINANT NEWCASTLE DISEASE VIRUSES By VALERIE CRISTINA MARCANO GOMEZ (Under the Direction of Claudio Afonso and Robert Gogal, Jr.) ABSTRACT In ovo vaccination has been used commercially for over 20 years to control avian diseases due to its significant advantages over conventional vaccination. The advantages of in ovo vaccination include a significant reduction in costs, induction of earlier immunity, uniform vaccine delivery, and reduction of stress. In ovo vaccination programs currently available for Newcastle disease virus (NDV) have limitations, including interference by maternal antibodies (MatAbs) and the inability to induce protective immunity until four weeks post vaccination. Current biosecurity measures and vaccination protocols have been unable to stop the occurrence of outbreaks with virulent vNDV around the world particularly in developing countries. Thus, it is imperative to develop new effective vaccines able to overcome the maternal antibody inhibition and confer the earliest protection against vNDV. The poultry industry needs vaccines able to boost both cellular and humoral immune response and to achieve clearance of the challenge virus without compromising the flock’s health. In a first set of experiments, attenuated recombinant NDV vaccines containing either an antisense chicken IL-4 insert (ZJ1-L-IL4R), IL-2 expressing variant (-IL2), IL-10 expressing variant (-IL-10) or IFNγ expressing variant (-IFNγ) were tested as vaccine candidates against homologous challenge with a genotype VIId NDV. Results show that strain ZJ1-L-IL4R may serve as a viable vaccine candidate for in ovo vaccination against NDV, as it compared favorably to the commercial strains regarding protection to challenge, yet displayed lower mortality rates compared with the in ovo live vaccine candidates for NDV.
    [Show full text]